Wall Street brokerages forecast that GW Pharmaceuticals PLC- (NASDAQ:GWPH) will report earnings per share of ($0.13) for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for GW Pharmaceuticals PLC-‘s earnings. The highest EPS estimate is $1.68 and the lowest is ($1.80). GW Pharmaceuticals PLC- posted earnings per share of ($1.26) in the same quarter last year, which would indicate a positive year over year growth rate of 89.7%. The company is scheduled to report its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that GW Pharmaceuticals PLC- will report full-year earnings of ($4.76) per share for the current financial year, with EPS estimates ranging from ($7.32) to $2.24. For the next financial year, analysts forecast that the business will post earnings of ($0.44) per share, with EPS estimates ranging from ($2.79) to $5.88. Zacks’ EPS calculations are an average based on a survey of research firms that follow GW Pharmaceuticals PLC-.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share for the quarter, beating the consensus estimate of ($2.48) by $0.80. GW Pharmaceuticals PLC- had a negative return on equity of 45.75% and a negative net margin of 458.79%. The company had revenue of $39.20 million during the quarter, compared to analysts’ expectations of $12.32 million. During the same period in the prior year, the business earned ($3.12) earnings per share. GW Pharmaceuticals PLC-‘s revenue for the quarter was up 1189.5% compared to the same quarter last year.
GWPH opened at $172.39 on Friday. GW Pharmaceuticals PLC- has a 1-year low of $90.14 and a 1-year high of $196.00. The company has a quick ratio of 7.19, a current ratio of 7.81 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $5.20 billion, a PE ratio of -16.32 and a beta of 2.57. The company has a 50 day simple moving average of $176.22.
In related news, CFO Scott M. Giacobello sold 4,224 shares of the firm’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $14.52, for a total value of $61,332.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Christopher J. Tovey sold 64,800 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $14.61, for a total value of $946,728.00. Following the completion of the transaction, the chief operating officer now directly owns 67,303 shares of the company’s stock, valued at $983,296.83. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,498,176 shares of company stock valued at $22,921,432. 5.50% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the business. Federated Investors Inc. PA lifted its holdings in shares of GW Pharmaceuticals PLC- by 23.5% during the first quarter. Federated Investors Inc. PA now owns 417,750 shares of the biopharmaceutical company’s stock valued at $70,420,000 after acquiring an additional 79,367 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of GW Pharmaceuticals PLC- by 80.4% during the first quarter. Victory Capital Management Inc. now owns 408,940 shares of the biopharmaceutical company’s stock valued at $68,935,000 after acquiring an additional 182,210 shares during the period. Marshall Wace North America L.P. lifted its holdings in shares of GW Pharmaceuticals PLC- by 1,564.3% during the first quarter. Marshall Wace North America L.P. now owns 316,899 shares of the biopharmaceutical company’s stock valued at $53,419,000 after acquiring an additional 297,858 shares during the period. Deutsche Bank AG lifted its holdings in shares of GW Pharmaceuticals PLC- by 18.2% during the fourth quarter. Deutsche Bank AG now owns 270,575 shares of the biopharmaceutical company’s stock valued at $26,350,000 after acquiring an additional 41,593 shares during the period. Finally, Millennium Management LLC bought a new position in shares of GW Pharmaceuticals PLC- during the fourth quarter valued at $15,685,000. 78.91% of the stock is owned by institutional investors.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Further Reading: The mechanics of the bid-ask spread in trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.